Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma

Experimental and Therapeutic Medicine

Volumn 3, Issue 5, 2012, Pages 763-770

  Zhong, Hua ^a   Xu, Lan ^a   Zhong, Ji Hua ^a   Xiao, Fei ^a   Liu, Qiang ^a   Huang, Hong Hui ^a   Chen, Fang Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diagnostic and prognostic marker; Diffuse large B cell lymphoma; miR 146a; miR 155

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FORMALDEHYDE; LACTATE DEHYDROGENASE; MICRORNA; MICRORNA 146A; MICRORNA 155; MYC PROTEIN; PARAFFIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMBEDDING; FEMALE; FORMALIN FIXED PARAFFIN EMBEDDING; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; REMISSION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TREATMENT OUTCOME;

EID: 84863359244     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.502     Document Type: Article

References (42)

1. Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8: 93-103, 2007.
2. Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6: 376-385, 2005.
3. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
4. Lawrie CH: MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? Cell Mol Med 12: 1432-1444, 2008.
5. Calin GA, Ferracin M, Cimmino A, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
6. Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
7. Kota SK and Balasubramanian S: Cancer therapy via modulation of microRNA levels: a promising future. Drug Discov Today 15: 733-740, 2010.
8. Coiffier B: Diffuse large cell lymphoma. Curr Opin Oncol 13: 325-334, 2001.
9. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
10. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.
11. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874, 2001.
12. Thompson RC, Herscovitch M, Zhao I, et al: NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem 286: 1675-1682, 2011.
13. Braun T, Carvalho G, Fabre C, et al: Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13: 748-758, 2006.
14. Taganov KD, Boldin MP, Chang KJ, et al: NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103: 12481-12486, 2006.
15. Li J, Smyth P, Flavin R, et al: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 7: 36, 2007.
16. Lawrie CH, Soneji S, Marafioti T, et al: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121: 1156-1161, 2007.
17. Nogai H, Dörken B and Lenz GJ: Pathogenesis of non-Hodgkin's lymphoma. Clin Oncol 29: 1803-1811, 2011.
18. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantificiation of microRNAs by stem-loop RT-PCR. Nucletic Acids Res 33: e179, 2005.
19. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
20. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005.
21. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005.
22. McManus MT: MicroRNAs and cancer. Semin Cancer Biol 13: 253-258, 2003.
23. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
24. Lawrie CH, Saunders NJ, Soneji S, et al: MicroRNA expression in lymphocyte development and malignancy. Leukemia 22: 1440-1446, 2008.
25. Lawrie CH, Chi JX, Taylor S, et al: Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 13: 1248-1260, 2009.
26. Xi Y, Nakajima G, Gavin E, et al: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 1668-1674, 2007.
27. Georgantas RW III, Hildreth R, Morisot S, et al: CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 104: 2750-2755, 2007.
28. Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102: 3627-3632, 2005.
29. Kluiver J, Poppema S, de Jong D, et al: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207: 243-249, 2005.
30. Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
31. Zhang H, Luo XQ, Zhang P, et al: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 4: e7826, 2009.
32. Wang Y, Li Z, He C, et al: MicroRNA expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 44: 191-197, 2010.
33. Visone R, Rassenti LZ, Veronese A, et al: Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 114: 3872-3879, 2009.
34. Roldo C, Missiaglia E, Hagan JP, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684, 2006.
35. Volinia S, Galasso M, Costinean S, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20: 589-599, 2010.
36. Monticelli S, Ansel KM, Xiao C, et al: MicroRNA profiling of the murine hematopoietic system. Genome Biol 6: R71, 2005.
37. Boominathan L: The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNA network. Cancer Metastasis Rev 29: 613-639, 2010.
38. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
39. Thai TH, Calado DP, Casola S, et al: Regulation of the germinal center response by microRNA-155. Science 316: 604-608, 2007.
40. Costinean S, Zanesi N, Pekarsky Y, et al: Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E (mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103: 7024-7029, 2006.
41. Boldin MP, Taganov KD, Rao DS, et al: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208: 1189-1201, 2011.
42. Lenz G, Wright GW, Emre NCT, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105: 13520-13525, 2008.